{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T03:21:45Z","timestamp":1782789705413,"version":"3.54.5"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100014941","name":"Cytokinetics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014941","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.ijcard.2020.08.067","type":"journal-article","created":{"date-parts":[[2020,8,22]],"date-time":"2020-08-22T19:26:09Z","timestamp":1598124369000},"page":"188-191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Angioedema with sacubitril\/valsartan: Trial-level meta-analysis of over 14,000 patients and real-world evidence to date"],"prefix":"10.1016","volume":"323","author":[{"given":"Sourbha S.","family":"Dani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarju","family":"Ganatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2020.08.067_bb0005","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2020.08.067_bb0010","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-Neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2020.08.067_bb0015","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ahj.2017.07.006","article-title":"Design for the sacubitril\/valsartan (LCZ696) compared with enalapril study of pediatric patients with heart failure due to systemic left ventricle systolic dysfunction (PANORAMA-HF study)","volume":"193","author":"Shaddy","year":"2017","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ijcard.2020.08.067_bb0020","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.004815","article-title":"From molecules to markets: broadening the focus of cardiovascular innovation","volume":"11","author":"Colaco","year":"2018","journal-title":"Circ Heart Fail."},{"key":"10.1016\/j.ijcard.2020.08.067_bb0025","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004302","article-title":"Adoption of Sacubitril\/valsartan for the Management of Patients with Heart Failure","volume":"11","author":"Sangaralingham","year":"2018","journal-title":"Circ Heart Fail."},{"key":"10.1016\/j.ijcard.2020.08.067_bb0030","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1161\/CIRCULATIONAHA.115.018622","article-title":"Combined angiotensin receptor antagonism and neprilysin inhibition","volume":"133","author":"Hubers","year":"2016","journal-title":"Circulation."},{"key":"10.1016\/j.ijcard.2020.08.067_bb0035","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1023\/B:PHAR.0000035902.67235.5c","article-title":"Use of angiotensin receptor antagonists in patients with ACE inhibitor induced angioedema","volume":"26","author":"Fuchs","year":"2004","journal-title":"Pharm. World Sci."},{"key":"10.1016\/j.ijcard.2020.08.067_bb0040","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1592\/phco.22.13.1173.33517","article-title":"Angiotensin II receptor blocker-associated angioedema: on the heels of ACE inhibitor angioedema","volume":"22","author":"Abdi","year":"2002","journal-title":"Pharmacotherapy."},{"key":"10.1016\/j.ijcard.2020.08.067_bb0045","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.amjcard.2012.03.034","article-title":"Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors","volume":"110","author":"Makani","year":"2012","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2020.08.067_bb0055","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","article-title":"Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial","volume":"17","author":"Kostis","year":"2004","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.ijcard.2020.08.067_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev."},{"key":"10.1016\/j.ijcard.2020.08.067_bb0065","doi-asserted-by":"crossref","first-page":"234","DOI":"10.2174\/1574886310666150729112903","article-title":"The role of disproportionality analysis of pharmacovigilance databases in safety regulatory actions: a systematic review","volume":"10","author":"Dias","year":"2015","journal-title":"Curr. Drug Saf."},{"key":"10.1016\/j.ijcard.2020.08.067_bb0070","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/jamia\/ocv063","article-title":"Use of data mining at the Food and Drug Administration","volume":"23","author":"Duggirala","year":"2016","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"10.1016\/j.ijcard.2020.08.067_bb0075","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","article-title":"Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database","volume":"72","author":"Montastruc","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ijcard.2020.08.067_bb0080","doi-asserted-by":"crossref","first-page":"e0157753","DOI":"10.1371\/journal.pone.0157753","article-title":"OpenVigil FDA - inspection of U.S. American adverse drug events pharmacovigilance data and novel clinical applications","volume":"11","author":"B\u00f6hm","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ijcard.2020.08.067_bb0085","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2020.08.067_bb0090","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-Neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2020.08.067_bb0095","first-page":"1","article-title":"Effect of Sacubitril-Valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial","author":"Desai","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2020.08.067_bb0100","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jchf.2016.12.018","article-title":"Early adoption of Sacubitril\/valsartan for patients with heart failure with reduced ejection fraction: insights from Get With The Guidelines-Heart Failure (GWTG-HF)","volume":"5","author":"Luo","year":"2017","journal-title":"JACC Heart Fail."},{"key":"10.1016\/j.ijcard.2020.08.067_bb0105","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry","volume":"72","author":"Greene","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2020.08.067_bb0110","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1001\/jamacardio.2019.4982","article-title":"Contemporary Patterns of Medicare and Medicaid Utilization and Associated Spending on Sacubitril\/Valsartan and Ivabradine in Heart Failure","volume":"5","author":"Sumarsono","year":"2019","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.ijcard.2020.08.067_bb0115","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1136\/bmj.38803.528113.55","article-title":"Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine","volume":"332","author":"McDowell","year":"2006","journal-title":"BMJ."},{"key":"10.1016\/j.ijcard.2020.08.067_bb0120","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the cooperative north Scandinavian Enalapril survival study (CONSENSUS)","volume":"316","author":"Group CTS","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2020.08.067_bb0125","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Yusuf","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2020.08.067_bb0130","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2020.08.067_bb0135","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2020.08.067_bb0140","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet."},{"key":"10.1016\/j.ijcard.2020.08.067_bb0145","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2020.08.067_bb0150","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2020.08.067_bb0155","series-title":"Measuring the Impact of Integrated Delivery Networks on physicians\u2019 Prescribing Preference. International Conference Data Science | ICDATA\u201919; Advanced Analytics, IQVIA, Plymouth Meeting, PA","first-page":"2019","author":"Wenzhe","year":"2019"},{"key":"10.1016\/j.ijcard.2020.08.067_bb0160","unstructured":"IQVIA: Real World Data. Available at: https:\/\/www.iqvia.com\/locations\/united-states\/solutions\/commercial-operations\/essential-information\/real-world-data\/ accessed July 25, 2020."},{"key":"10.1016\/j.ijcard.2020.08.067_bb0165","first-page":"A362","article-title":"National Trends in use of Sacubitril\/valsartan","volume":"13","author":"Ozaki","year":"2020","journal-title":"Circulation: Cardiovascular Quality and Outcomes"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527320336500?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527320336500?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T20:50:35Z","timestamp":1759092635000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527320336500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":32,"alternative-id":["S0167527320336500"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2020.08.067","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Angioedema with sacubitril\/valsartan: Trial-level meta-analysis of over 14,000 patients and real-world evidence to date","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2020.08.067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}